SOCS proteins take part in a classical negative feedback loop to attenuate cytokine signaling. Although STAT family members positively modulate Socs gene expression, little else is known about Socs gene regulation. Here, we identify functional binding sites for GFI-1B, a proto-oncogenic transcriptional repressor, in the promoters of murine Socs1 and Socs3. Thus, mutating these sites relieved transcriptional repression, as determined by luciferase reporter assays of transiently transfected erythropoietin-responsive 32D-EpoR and HCD57 cells. Furthermore, cotransfection of Gfi-1B expression plasmid repressed reporter activity of wild-type (but not mutagenized) Socs1 and Socs3 promoters, strongly suggestive of direct GFI-1B binding to these promoters. In addition, overexpression of Gfi-1B resulted in reduced transcript levels of Socs1 and Socs3, but not Socs2 or Cis. Upon stimulation with erythropoietin, Socs transcripts were rapidly induced, whereas Gfi-1B mRNA was downregulated. Interestingly, the latter effect appears to rely on STAT5 activity, but not on phosphoinositide 3-kinase or MAPK pathways. Thus, cytokine-mediated STAT5 activation allows relief of direct repression by GFI-1B of the Socs1 and Socs3 promoters, but apparently not of the Socs2 and Cis promoters. This constitutes a previously undescribed mode of controlling cytokine responsiveness, through the direct repression of a tumor suppressor (SOCS1) by a proto-oncoprotein (GFI-1B).
Responsiveness to cytokines depends upon a balance of positive and negative regulators. The latter includes at least three protein classes. SHP1 (SH2 domain-containing protein-tyrosine phosphatase-1), PIAS (protein inhibitors of activated STAT proteins), and SOCS (suppressors of cytokine signaling) (1) . There are at least eight members of the SOCS family, each of which contains a variable N-terminal region, a central SH2 domain, and a conserved C-terminal SOCS box domain (2) (3) (4) (5) (6) (7) (8) . Several SOCS family members have been shown to negatively regulate cytokine signaling in vitro and to result in severe physiological effects when disrupted by gene targeting in mice (9 -14) .
Although the role of SOCS proteins in modulating cytokine signaling has been extensively studied, less is known about the mechanisms that control Socs gene expression. Others have shown that a plethora of cytokines induces Socs expression at a transcriptional level and that there are functional binding sites for cytokine-activated STAT (signal transducer and activator of transcription) family members in the promoters of Cis (cytokine-inducible SH2 protein) and Socs3 (15) (16) (17) . Furthermore, Socs1 expression is controlled, in part, through translational repression (18, 19) . Recent evidence suggests that, in the majority of examined human hepatocellular carcinomas, Socs1 is transcriptionally silenced through aberrant methylation in its CpG islands (20, 21) . Restored Socs1 expression suppresses both growth rate and anchorage-independent growth of such human hepatocellular carcinoma cells, supporting the notion that SOCS1 may indeed be a tumor suppressor.
We now demonstrate the role of a proto-oncogenic transcriptional repressor, GFI-1B (growth factor independence), in regulating Socs1 and Socs3 expression in response to erythropoietin (EPO). 1 Gfi-1B was cloned based on its sequence similarity to Gfi-1, a target of provirus integration in T-cell lymphoma lines selected for interleukin-2 independence in culture and in primary retrovirus-induced lymphomas (22, 23) .
Although similar in their consensus DNA recognition sequences and domain organization, Gfi-1B is preferentially expressed in erythropoietic organs such as bone marrow and spleen, whereas Gfi-1 is more abundant in the lymphopoietic thymus (22) . 32D-EpoR and HCD57, two EPO-responsive cell lines, express Gfi-1B, but not Gfi-1. In response to EPO stimulation, Socs1, Socs2, Socs3, and Cis transcript levels increase, whereas Gfi-1B levels decline. We provide evidence that GFI-1B directly represses the promoters of Socs1 and Socs3 through specific DNA-binding elements and that EPO-induced Gfi-1B diminution relies on STAT5 activity, but is independent of phosphoinositide 3-kinase (PI3K) or MAPK pathways. Thus, cytokine-mediated activation of STAT5 allows relief of direct repression by GFI-1B of distinct Socs promoters. In summary, we have identified a novel mechanism for controlling responsiveness to cytokines; a mechanism for differential regulation of Socs genes; and new targets to account for the oncogenic properties of GFI-1 family members, which have previously been shown to directly repress genes that control the cell cycle and apoptosis (22, 24) .
EXPERIMENTAL PROCEDURES
Plasmids and Mutagenesis-Site-directed mutagenesis was achieved using the QuikChange TM XL site-directed mutagenesis kit (Stratagene) following the manufacturer's instructions. Gfi-1B cDNA was derived from wild-type C57BL/6 mouse spleen RNA using the oligonucleotides 5Ј-ATGAGGATCCCCAGGGCAAGTGTGGAGGTTCGTGG-3Ј and 5Ј-CTGAGAATTCAGCGAGACACACTAAAGCAGGCGGC-3Ј and the Advantage TM One-Step RT-PCR kit (CLONTECH). After sequence confirmation and digestion with BamHI and EcoRI, it was cloned into the mammalian expression plasmid pMex(neo) (provided by Dr. Stephanie Watowich) to generate pMex-Gfi-1B or into pcDNA3.1 (Invitrogen). pMex-P2A-Gfi-1B was derived from pMex-Gfi-1B using the primer 5Ј-GCACGCAGAAAAATGGCACGGTCCTTTCTAGTG-3Ј and its complementary primer.
Genomic DNA clones containing Socs1 or Socs2 were isolated from a 129(J1) genomic library (25) , and the 5Ј-flanking regions were mapped. To clone the Socs1 5Ј-flanking region into a luciferase reporter plasmid, a 3.1-kb fragment obtained by HindIII digestion and blunting, followed by partial XhoI digestion, was inserted into SmaI-XhoI pGL3-basic (Promega) to generate Clone 9. The Socs2 5Ј-flanking region was cloned by inserting a 6.5-kb BglII-BstXI (blunted) fragment into pGL3-basic.
For mutagenesis of the Socs1 promoter, the following oligonucleotides and their respective complementary oligonucleotides were employed: 5Ј-AGGACAAACTGGGTCACGAAACCACACAGT-3Ј for the upstream GFI-1B-binding site, 5Ј-ACAGCTTTTTTTGGGGTCACAGC CCCGCCCGGGGCC-3Ј for the downstream GFI-1B-binding site, 5Ј-CTAGCTAGCCGGGTACGAAGAAGGGTCGAGATTGC-3Ј for the upstream STAT-binding site, and 5Ј-GAGAGAACCCGAAAGACTAGGC-GGAAAGAGAAACCG-3Ј for the downstream STAT-binding site. For each construct, a 1.9-kb SacII-EspI fragment containing the appropriate mutation(s) was subcloned into the wild-type backbone and subsequently sequenced to ensure that no unexpected mutations were present.
For mutagenesis of the Socs3 promoter, the primer 5Ј-GCTCTACT-GGGTCACAGGTCATGACTAGTCCTTGCTCATGG-3Ј and its complementary primer were employed to mutate the GFI-1B-binding site in the previously described Clone 6, containing 2.8 kb of the Socs3 5Ј-flanking region in the pGL3-basic vector (17) . A 1.5-kb AflII-BstXI fragment harboring this mutation was subcloned into the backbone of either wild-type Clone 6 or Clone 6D2, in which a critical STAT-binding element is destroyed (17) .
Cell Culture and Stable Cell Line Generation-The culture conditions for 32D cells that ectopically express either wild-type or mutant erythropoietin receptor (EpoR), and HCD57 cells, which naturally express EpoR, have been described (26, 27) . NIH3T3 cells were passaged in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. To generate cell lines that constitutively overexpress Gfi-1B, pMex-Gfi-1B (or the pMex vector as a control) was used to electroporate 32D-EpoR or HCD57 cells (25 g of DNA/10 7 cells; pulsed at 25 microfarads and 400 V). Stable transfectants were selected in 0.6 mg/ml G418 (for 32D-EpoR cells) or 1.0 mg/ml G418 (for HCD57 cells). To generate cell lines that inducibly overexpress Gfi-1B, a KpnI-EcoRV Gfi-1B fragment was shuttled from pcDNA3.1 into the metallothionein promoter-containing MT-CB6 ϩ (neo) eukaryotic expression vector (supplied by Dr. Frank Rauscher III). After electroporation, G418 selection, limiting dilution, and expansion, single clones were tested for their -fold induction of the Gfi-1B transcript upon addition of 100 M zinc sulfate. To generate cell lines that stably express dominant-negative Stat5, the C-terminally truncated ⌬Stat5B (provided by Dr. Alice Mui) was subcloned into pcDNA3.1. The resulting construct was linearized with PvuI and used to electroporate 32D-EpoR or HCD57 cells as described above. Stable transfectants were selected in G418 as described above and analyzed as subpools rather than single clones.
Transient Transfections and Reporter Assays-32D-EpoR, HCD57, or NIH3T3 cells were transfected with 5 g of total plasmid DNA/10 6 cells using Effectene TM transfection reagent (QIAGEN Inc.) following the manufacturer's guidelines. For mutant promoter analyses, 4.5 g of carefully quantitated pGL3-basic-based plasmid, which encodes firefly luciferase, was cotransfected with 0.5 g of pRL-TK (Promega), which encodes Renilla luciferase and is used as an internal control reporter for normalizing transfection efficiency. For transient Gfi-1B overexpression studies, 4 g of either pMex-Gfi-1B or pMex-P2A-Gfi-1B was cotransfected with 0.5 g of Socs promoter-containing pGL3-basic and 0.5 g of pRL-TK. Cell lysates were prepared 36 h post-transfection and analyzed for luciferase activity using the Dual-Luciferase ® reporter assay system (Promega). The indicated relative reporter activities take into account normalized transfection efficiency and, where applicable, discrepancies in plasmid size.
Northern Blot Analysis-10 g of total RNA, isolated from cells using Trizol reagent (Invitrogen), was separated by gel electrophoresis; transferred to nylon membranes; and hybridized with [␣-32 P]dCTP-labeled DNA probes, derived from full-length cDNA template using the PrimeIt ® II random primer labeling kit (Stratagene). After hybridization for 2 h at 65°C using QuikHyb ® hybridization solution (Stratagene), blots were washed twice for 20 min at 65°C with 0.1ϫ SSC and 0.1% SDS.
Electrophoretic Mobility Shift Assay (EMSA)-Nuclear extracts were prepared from HCD57 or 32D-EpoR cells as described (26) . Gfi-1B was in vitro transcribed and translated by the TNT ® T7 coupled reticulocyte lysate system (Promega). EMSAs were done with the following oligonucleotides, each annealed to its complementary strand: 5Ј-AGGACAAACTGAATCACGAAACCACACAGT-3Ј for the upstream GFI-1B-binding site in the Socs1 promoter; 5Ј-ACAGCTTTTTTTGGA-ATCACAGCCCCGCCCGGGGCC-3Ј for the downstream GFI-1B-binding site in the Socs1 promoter; 5Ј-GCTCTACTGGGTCACAAATCATG-ACTAGTCCTTGCTCATGG-3Ј for the Socs3 promoter GFI-1B-binding site, 5Ј-GCTAGCCGGGTTCCAAGAAGGGTCGAGAT-3Ј for the upstream STAT-binding site in the Socs1 promoter, and 5Ј-CCCGAAAG-ACTTGCCGGAAAGAGAAACCG-3Ј for the downstream STAT-binding site in the Socs1 promoter. Mutant oligonucleotides were used for competition studies: AATC to GGTC for GFI-1B binding and TTNC-NNNAA to TANGNNNAA for STAT5 binding. Wild-type doublestranded oligonucleotides were end-labeled with [␥- 32 P]ATP and T4 polynucleotide kinase (New England Biolabs Inc.). Either 10 g of nuclear extract or one-tenth of the Gfi-1B translated in vitro from RNA derived from 1 g of pcDNA3.1-Gfi-1B was incubated in binding buffer (10 mM HEPES, pH 7.6, 0.5 mM dithiothreitol, 50 mM NaCl, 0.05% (v/v) Nonidet P-40, 10% (v/v) glycerol, 50 ng/l poly(dI-dC) (Amersham Biosciences, Inc.), and 2.5 mg/ml nonfat milk) at room temperature for 20 min prior to addition of labeled probe. For supershift studies, nuclear extracts were preincubated on ice for 1 h with 1 g of anti-STAT5 or anti-GFI-1B antibody (Santa Cruz Biotechnology). To compete for protein binding, excess wild-type or mutant double-stranded oligonucleotides were included in binding buffer (40 -200-fold relative to labeled probe). Labeled probe (25,000 cpm) was added, and the binding reaction was incubated at room temperature for 30 min. Samples were then electrophoresed at 160 V on nondenaturing 5% polyacrylamide gels at 4°C for 3 h in 0.5ϫ Tris borate/EDTA, followed by gel drying and autoradiography.
RESULTS

Transcriptional Repression of Select Socs
Promoters by GFI-1B-Our initial goal was to dissect the mechanisms of Socs1 transcriptional induction by EPO. During the initial stages of this analysis, smaller promoter fragments were found to possess greater activity than larger fragments (data not shown), suggesting that sequences upstream of the proximal promoter may possess binding sites for functionally relevant repressors. With MatInspector Version 2.2 (28), we found two potential GFI-1/GFI-1B-binding sites, each containing a 100% conserved AATC core and overall 8 out of 12 nucleotide matches to the consensus sequence determined by binding of random oligonucleotides to a glutathione S-transferase-tagged GFI-1 or GFI-1B fusion protein (22, 29) . As shown in Fig. 1A , these two sites reside at Ϫ900 to Ϫ911 and at Ϫ763 at Ϫ774 relative to the transcriptional start site previously determined (19) , whereas two putative STAT-binding elements reside at Ϫ103 to Ϫ111 and at Ϫ467 to Ϫ475 (30). Gfi-1B (but not Gfi-1) is highly expressed in two EPO-responsive cell lines, 32D-EpoR and HCD57 (26, 27) , as determined by Northern analysis (Fig.  1B ). This concurs with previous findings that Gfi-1B is preferentially expressed over Gfi-1 in mouse erythropoietic organs, bone marrow and spleen (22) . From then on, we focused our interests on Gfi-1B.
The aforementioned cell lines, which are EPO-dependent for proliferation and survival and die within 24 h of EPO deprivation, were deprived of EPO (but no other components of their regular growth medium) for 16 h, followed by stimulation with 1 unit/ml EPO (Fig. 1C) . Whereas Socs transcripts were induced within 1 h, Gfi-1B mRNA was rapidly down-regulated (the mRNA half-life is Ͻ1 h in the absence or presence of EPO as determined by actinomycin D treatment) (data not shown). The inverse correlation between Socs and Gfi-1B transcript levels upon EPO stimulation is consistent with the latter repressing the former.
To assess the functional relevance of these potential GFI-1B-binding sites, we performed EMSAs using in vitro translated GFI-1B. Fig. 1D (lane 2) shows two major [
35 S]methioninelabeled products, the larger one corresponding to the expected full-length GFI-1B protein and the shorter one, as seen previously (22) , probably arising from an internal AUG start codon and thus expected to contain the C-terminal DNA-binding domain. A 36-or 30-bp probe corresponding to Socs1 promoter fragments containing the downstream (Ϫ763 to Ϫ774) (Fig. 1E,  lanes 1-6) or upstream (Ϫ900 to Ϫ911) (lanes 7-12) GFI-1B-binding site, respectively, was used for binding either in vitro translated GFI-1B (Fig. 1E, ϩ) or reticulocyte lysate negative control (Ϫ) in the absence or presence of a 40-or 200-fold excess of unlabeled wild-type or mutant (AATC to GGTC) competitor. The two major shifted bands, likely corresponding to the two in vitro translation products, diminished when the binding reaction was co-incubated with excess wild-type (but not mutant) competitor. Thus, we established specific binding of GFI-1B to the appropriate promoter elements in vitro.
These conclusions were further supported when nuclear extracts of 32D-EpoR or HCD57 cells were employed (Fig. 1F ). Cells were deprived of EPO as described above to enhance accumulation of endogenous GFI-1B, and nuclear extracts were prepared as described previously (26) . To establish the identity and specificity of GFI-1B binding, equal amounts of nuclear extract were co-incubated either with anti-GFI-1B antibody (Fig. 1F, G) or irrelevant control antibody (C) or with 100-fold excess unlabeled wild-type (W) or mutant (M) competitor. Anti-GFI-1B (but not control) antibody could supershift the EMSA complexes (Fig. 1F, lanes 2 and 8, arrow) , confirming GFI-1B binding. This complex was diminished upon specific competition (Fig. 1F, lanes 4 and 10) . Furthermore, GFI-1B binding was indiscernible with nuclear extracts prepared from EPOstimulated cells (Fig. 1F, lanes 6 and 12) . Thus, down-regulation of Gfi-1B transcript levels (Fig. 1C ) parallels down-regulation of protein activity, strengthening the biological relevance of our findings.
To determine the functionality of these sites and their interplay with STAT-binding elements in a cellular setting, we compared the activities of various Socs1 promoter-driven luciferase reporter constructs, which were generated as described under "Experimental Procedures." First of all, STAT5 binding to the putative elements identified in Fig. 1A was confirmed by EMSA using nuclear extracts from EPO-stimulated cells ( Fig.  2A) , in analogy to the experiment described in Fig. 1F . Either element could indeed bind to STAT5, as confirmed by supershift with anti-STAT5 antibody (S; Fig. 2A , lanes 2 and 7, arrow), but not with an irrelevant control antibody (C; lanes 3 and 8), and by specific competition (lanes 4, 5, 9, and 10).
The parental construct (Clone 9) contains 2.4 kb upstream of the Socs1 transcriptional start site and untranslated exon 1, but ends immediately upstream of the start codon. This reporter activity is strictly EPO-dependent (data not shown), and all values in Fig. 2B derive from reporter assays of 32D-EpoR cells continuously passaged in EPO and therefore represent steady-state EPO signaling. Mutating either one or both of the FIG. 1. GFI-1B-binding sites in the murine Socs1 promoter and regulation of Gfi-1B and Socs transcripts by EPO. A, the mouse Socs1 promoter sequence, which corresponds to bp 10873-11872 of GenBank TM /EBI Data Bank accession number Z47352, contains two putative GFI-1B-binding sites (22) , which are in boldface and underlined, and two putative STAT-binding elements (TTNCNNNAA) (30) , which are in boldface. B, Gfi-1B (but not Gfi-1) is expressed in 32D-EpoR and HCD57 cells, as determined by Northern analysis described under "Experimental Procedures." C, 32D-EpoR cells were deprived of EPO for 16 h, followed by stimulation with 1 unit/ml EPO and RNA isolation at the indicated time points for Northern analysis. D, [ 35 S]methionine-labeled, in vitro translated GFI-1B was electrophoresed by 10% SDS-PAGE and visualized by autoradiography. Lane 1 shows the results of a reaction without added Gfi-1B expression plasmid; lane 2 contains the in vitro translation products of pcDNA3.1-Gfi-1B. E, the following 32 P-labeled double-stranded oligonucleotide probes were used in EMSA: a 36-bp probe including the putative GFI-1B-binding site spanning Ϫ763 to Ϫ774 of the Socs1 promoter (lanes 1-6) and a 30-bp probe including the putative GFI-1B-binding site spanning Ϫ900 to Ϫ911 (lanes 7-12) . Lanes 1 and 7 contain the oligonucleotide probe and reticulocyte lysate only (negative control). In lanes 3, 5, 9, and 11, the corresponding oligonucleotide competitors were added at 40-fold excess, whereas in lanes 4, 6, 10, and 12, they were added at 200-fold excess. IVT, in vitro translation product; Comp, oligonucleotide competitor; WT, wild-type unlabeled oligonucleotide competitor; MUT, mutant (AATC to GGTC) unlabeled oligonucleotide competitor. F, the same probes described for E were tested for binding to nuclear extracts. Each lane used 10 g of nuclear extract from 32D-EpoR cells deprived of EPO for 16 h (lanes 1-5 and 7-11 ) or deprived of EPO and then stimulated with 1 unit/ml EPO for 2 h (lanes 6 and 12) . For supershift analyses, nuclear extracts were incubated with either anti-GFI-1B antibody (G; lanes 2 and 8) or an irrelevant control antibody (C; lanes 3 and 9) . In lanes 4, 5, 10, and 11, the corresponding oligonucleotide competitors were added at 100-fold excess. Ab, antibody; Comp, competitor; W, wild-type competitor; M, mutant competitor.
GFI-1B-binding sites (AATC to GGTC) resulted in a 2.2-3.1-fold enhancement of reporter activity, suggesting relief of transcriptional repression and cooperativity between the two GFI-1B-binding sites (Clones 9G1, 9G2, and 9G1G2) (Fig. 2B) . Furthermore, mutating both STAT5-binding elements (TTNC-NNNAA to TANGNNNAA) reduced reporter activity to ϳ11% of the wild type (Clone 9S1S2 versus Clone 9). Interestingly, mutating all four elements resulted in reporter activity that was 45% of the wild type, a 4.0-fold increase over the STAT5-binding element mutant (Clone 9GGSS compared with Clone 9S1S2). This suggests that Socs1 promoter activity can be significant even in the absence of STAT5 binding and that GFI-1B plays a critical role in setting the base-line level of wild-type promoter activity. Furthermore, the ability of GFI-1B to repress reporter activity in the absence of STAT5 binding suggests that its mechanism of action does not solely, if at all, rely on prevention of STAT5 binding. Similar results were obtained with HCD57 cells (data not shown).
To determine whether overexpression of Gfi-1B alone is sufficient to repress Socs1 promoter activity and to assess its role in the regulation of other Socs promoters, Clone 9 (Fig. 3A, bars  4 -6) , a Socs2 promoter reporter (bars 7-9), or a Socs3 promoter reporter (bars 10 -12) was cotransfected with the empty vector pMex (bars 1, 4, 7, and 10), pMex-Gfi-1B (bars 2, 5, 8, and 11) , or pMex-P2A-Gfi-1B (bars 3, 6, 9, and 12), the latter encoding a debilitating point mutation in the SNAG (Snail/Gfi-1) repressor domain (22, 31) . To normalize transfection efficiency, pRL-TK, which lacks consensus binding sites for GFI-1B, was used. Overexpressing Gfi-1B (but not the P2A mutant) repressed Socs1 and Socs3 (but apparently not Socs2) promoter activity, suggesting that GFI-1B differentially regulates Socs genes and requires a functional repressor domain to do so. Indeed, examination of 2.0 kb of the 5Ј-flanking sequence of Socs2 revealed no obviously potential GFI-1B-binding sites. Similar results were seen with both 32D-EpoR and HCD57 cells.
Because gene expression can be regulated by distal or downstream as well as proximal or upstream elements, we attempted to confirm the above conclusions by surveying endogenous Socs transcript levels in the absence or presence of Gfi-1B overexpression. Fig. 3B shows the effects of sustained Gfi-1B overexpression on the induction of Socs transcripts after withdrawal of (Ϫ) and subsequent stimulation with EPO. Socs1 and Socs3 transcript levels were slightly reduced at all time points, whereas Socs2 and Cis were unaltered upon comparison of subpools of 32D-EpoR cells stably overexpressing Gfi-1B (Fig. 3B , right panels) with subpools harboring the empty vector (left panels). Furthermore, we generated multiple 32D-EpoR lines that stably express Gfi-1B from an inducible metallothionein promoter. Continuously passaged in EPO, these cells were treated with 100 M zinc sulfate to induce Gfi-1B overexpression, which again resulted in decreased Socs1 and Socs3 transcript levels, but unaltered Socs2 and Cis transcript levels (Fig. 3C) .
This led us to analyze the Socs3 promoter, which has been cloned and characterized (17) . Sequence analysis revealed the presence of one putative GFI-1B-binding site located at Ϫ2057 to Ϫ2068 relative to the transcriptional start site (Fig. 4A) . Indeed, mutation of the AATC core to GGTC resulted in a 1.8-fold enhancement of reporter activity (Clone 6-G compared with wild-type Clone 6) in 32D-EpoR and HCD57 cells continuously passaged in EPO. Furthermore, Clone 6D2, in which both putative STAT-binding elements are disrupted, resulted in ϳ37% promoter activity relative to Clone 6. Again, mutating the GFI-1B-binding site resulted in an ϳ2-fold increase in promoter activity in the STAT binding-defective mutant (Clone 6D2-G versus Clone 6D2). Thus, the repressive activity of GFI-1B does not appear to rely on STAT binding to the Socs3 promoter. To confirm the binding specificity of the relevant promoter fragment for in vitro translated GFI-1B (Fig. 1D) or GFI-1B from nuclear extracts, EMSA was conducted using a 41-bp fragment of the Socs3 5Ј-flanking region, which includes the putative GFI-1B-binding element. Supershift studies as well as specific and nonspecific competitors were employed, analogous to the experiments described for Fig. 1E (Fig. 4B) and Fig. 1F (Fig. 4C) . Again, GFI-1B specifically bound to the relevant promoter fragment in vitro.
To assess the directness of GFI-1B regulation of the Socs1 and Socs3 promoters, highly transfectable NIH3T3 fibroblasts were also used. These cells express Socs1 and Socs3, but not Socs2, Cis, or Gfi-1B, as determined by Northern analysis (data not shown). As shown in Fig. 5 , mutant promoters lacking functional GFI-1B-binding sites were not derepressed compared with their respective wild-type promoters, presumably because of the lack of endogenous Gfi-1B expression (bars 3 and 5 for Socs1 and bars 7 and 9 for Socs3). However, cotransfection of pMex-Gfi-1B repressed the promoter activity of both Socs1 (Fig. 5, bars 3 and 4) and Socs3 (bars 7 and 8). On the other hand, promoters in which the GFI-1B-binding sites have been mutated failed to respond to exogenous Gfi-1B (bars 5 and 6 for Socs1 and bars 9 and 10 for Socs3), confirming direct binding of GFI-1B to both the Socs1 and Socs3 promoters.
Consistent with GFI-1B-mediated repression of select Socs promoters, SOCS proteins and GFI-1B manifested opposing biological effects. Whereas stable overexpression of Gfi-1B in 32D-EpoR cells resulted in enhanced proliferation (Fig. 6) , overexpression of Socs1 or Socs3 reduced cell proliferation. 2 Although the former effect can be explained, in part, by previous observations that GFI-1B represses the p21
Waf1 promoter (22) , it also is compatible with our findings that GFI-1B represses the promoters of certain Socs family members, which negatively regulate cytokine-induced cell proliferation.
STAT5-dependent Diminution of Gfi-1B Levels in Response to EPO-Having shown that
Gfi-1B levels rapidly declined in 2 A. G. Jegalian and H. Wu, manuscript in preparation.
FIG. 3. Differential expression of Socs genes in response to
Gfi-1B overexpression. A, 32D-EpoR cells were transiently cotransfected with 1) pRL-TK for normalization; 2) the pMex, pMex-Gfi-1B, or pMex-P2A-Gfi-1B expression plasmid (the latter encodes a mutant form of Gfi-1B defective in transcriptional repression); and 3) a pGL3-basic-based reporter construct containing either Socs1 (Clone 9), Socs2, or Socs3 promoter. Normalized relative reporter activity values (means Ϯ S.D.) are based on the results of five independent experiments and were similar in 32D-EpoR and HCD57 cells. B, 32D-EpoR cells stably harboring pMex (left panels) or pMex-Gfi-1B (right panels) were deprived of EPO for 16 h and then stimulated with 1 unit/ml EPO for the indicated times, at which point, RNA was isolated for Northern analysis. C, parental 32D-EpoR cells or individual Clones A and B, which inducibly overexpress Gfi-1B from a metallothionein promoter, were grown in 1 unit/ml EPO in the absence or presence of 100 M zinc sulfate for 24 h. RNA was isolated and subjected to Northern blot analysis.
FIG. 4. Role of GFI-1B in regulating Socs3 promoter activity.
A, a putative GFI-1B-binding site spans Ϫ2057 to Ϫ2068 of the murine Socs3 promoter, relative to the transcriptional start site previously determined (17) . G, GFI-1B-binding site; S, STAT-binding site. Ovals represent the luciferase reporter. Clone 6 consists of the wild-type full-length Socs3 5Ј-flanking region previously characterized, whereas Clone 6D2 was derived by deleting two putative STAT-binding elements in Clone 6 (17) . The core sequence AATC was mutated to GGTC in Clones 6-G and 6D2-G, which were derived from Clones 6 and 6D2, respectively. Transient transfections and luciferase assays were performed as described for Fig. 2B . Values are based on the results of six independent experiments (means Ϯ S.D.) and were similar in 32D-EpoR and HCD57 cells. B, a 41-bp probe containing this putative GFI-1B-binding site was used for EMSA as described in the legend to Fig. 1E . Lane 1 contains the oligonucleotide probe and reticulocyte lysate only (negative control). In lanes 3 and 5, the corresponding oligonucleotide competitors were added at 40-fold excess and, in lanes 4 and 6, at 200-fold excess. IVT, in vitro translation product; Comp, oligonucleotide competitor; WT, wild-type unlabeled oligonucleotide competitor; MUT, mutant (AATC to GGTC) unlabeled oligonucleotide competitor. C, this probe was used for EMSA with nuclear extracts as described in the legend to Fig. 1F . Each lane used 10 g of nuclear extract from 32D-EpoR cells deprived of EPO for 16 h (lanes 1-5) or deprived of EPO and then stimulated with 1 unit/ml EPO for 2 h (lane 6). For supershift analysis, nuclear extracts were incubated with either anti-GFI-1B antibody (G; lane 2) or an irrelevant control antibody (C; lane 3). In lanes 4 and 5, the corresponding oligonucleotide competitors were added at 100-fold excess. Ab, antibody; Comp, competitor; W, wild-type competitor; M, mutant competitor.
response to EPO (Fig. 1C) , we dissected the pathways downstream of EPO that might account for this effect. The first approach made use of 32D cell lines that express similar levels of previously characterized EpoR mutants, each of which carries a single cytoplasmic tyrosine residue (26, 32 The second approach made use of chemical inhibitors of MAPK (PD98059) and PI3K (LY294002) and a dominant-negative form of STAT5. 32D-EpoR cells were cultured without EPO for 14 h and then pretreated for 2 h with Me 2 SO carrier control, 5 M LY294002, or 50 M PD98059, followed by 2 h of treatment with 1 unit/ml EPO in the continued presence of chemical inhibitors. Northern analysis revealed that neither chemical inhibitor prevented EPO-mediated Gfi-1B down-regulation; and thus, this effect appears to be independent of PI3K and MAPK (Fig. 7B) . To assess the role of STAT5 in Gfi-1B regulation, 32D-EpoR cells stably carrying the pcDNA3.1 vector or stably expressing C-terminally truncated dominant-negative Stat5 (⌬Stat5) (34) were deprived of EPO for 16 h and then stimulated with EPO for either 1 or 3 h. As shown in Fig.  7C , whereas Gfi-1B down-regulation occurred in the vectortransfected controls, it did not occur in cells overexpressing ⌬Stat5. Taking together the results of Fig. 7 (A-C) , we conclude that the C terminus of STAT5 is necessary for EPO-mediated Gfi-1B reduction, whereas MAPK and PI3K are neither sufficient nor necessary for Gfi-1B diminution.
To determine whether STAT5-dependent Gfi-1B down-regulation requires new protein synthesis, 32D-EpoR cells were deprived of EPO for 14 h and then pretreated with 50 g/ml cycloheximide before EPO stimulation for 2 h. As shown in Fig.  7D , cycloheximide prevented EPO-mediated Gfi-1B down-regulation. Similar results were seen with HCD57 cells. Thus, it is likely that STAT5 protein, whose half-life is several hours (data not shown), activates intermediate target genes rather than acting directly to suppress Gfi-1B levels. (26) , were deprived of EPO for 16 h and then stimulated with 1 unit/ml EPO. Northern analysis was performed as described under "Experimental Procedures." WT, wild type. B, after 2 h of pretreatment and in the continued presence of Me 2 SO carrier control (DMSO), 5 M LY294002 (PI3K inhibitor), or 50 M PD98059 (MAPK inhibitor), EPOstarved 32D-EpoR cells were stimulated with 1 unit/ml EPO. RNA was isolated after 2 h and subjected to Northern analysis. C, 32D-EpoR cells stably carrying the pcDNA3.1 empty vector or stably expressing Cterminally truncated dominant-negative Stat5 (⌬Stat5) (34) were deprived of EPO for 16 h and then stimulated with 1 unit/ml EPO for either 1 or 3 h. Northern analysis was performed as described under "Experimental Procedures." D, 32D-EpoR cells were deprived of EPO for 14 h and then pretreated or not with 50 g/ml cycloheximide (CHX) for 30 min before stimulation with 1 unit/ml EPO for 2 h. Northern analysis was performed as described under "Experimental Procedures." one member, SOCS1, being a tumor suppressor (20, 21) . Gfi-1 and Gfi-1B, on the other hand, are proto-oncogenes, the former being implicated in T-cell lymphomagenesis and the latter found to be a target of provirus integration in a subset of B-cell lymphomas induced by Moloney murine leukemia virus in Emyc transgenic, pim-1/pim-2 null mice (22, 35) . In this study, we have demonstrated a link between Gfi-1B and Socs1 as well as Socs3. Namely, we have identified functional binding sites for GFI-1B in the promoters of Socs1 (Ϫ763 to Ϫ774 and Ϫ900 to Ϫ911) and Socs3 (Ϫ2057 to Ϫ2068). Furthermore, disrupting the GFI-1B-binding sites in STAT5 binding-defective promoter mutants still allows relief of the repressive effects of GFI-1B, suggesting that GFI-1B does not act solely, if at all, by interfering with STAT5 binding to its corresponding sites.
Indeed, the mechanism of action of GFI-1B as a transcriptional repressor is not clear. GFI-1B, like GFI-1, contains a 20-amino acid N-terminal SNAG repressor domain, and it has been demonstrated for GFI-1 (but not for GFI-1B) that its repressive function may be position-and orientation-independent (31) . Recently, GFI-1 was shown to interact with PIAS3 (which specifically inhibits STAT3-mediated transcription of target genes), to inhibit PIAS3 action, and therefore to enhance STAT3-mediated transcriptional activation (36) . Extending this finding to GFI-1B, however, is not necessarily warranted because the SNAG domain of GFI-1 is not sufficient for binding to PIAS3, and the sequence similarity between GFI-1 and GFI-1B is limited to the SNAG domain and C-terminal zinc fingers (22) .
Our finding that GFI-1B is an important negative regulator of the Socs1 promoter may be compatible with recent evidence suggesting that transcriptional silencing of Socs1 through aberrant methylation in its CpG islands may contribute to oncogenesis (20, 21) . It would be interesting to determine, for instance, if GFI-1B interacts with one of the components of the methyl-CpG-binding MeCP1 complex to stabilize it (37) . One must search for GFI-1B-binding proteins to begin to address such issues. However, given the relatively long distances of GFI-1B-binding sites from the transcriptional start sites of target genes (1.5 kb for p21
Waf1 , 0.8 -0.9 kb for Socs1, and 2.1 kb for Socs3), association with a complex silencer region is likely in each case.
In addition, we have shown that EPO down-regulates Gfi-1B transcript levels through a mechanism independent of PI3K and MAPK, but requiring the STAT5 C terminus, which contains its transcriptional activation domain. Indeed, new protein synthesis is required for STAT5-mediated Gfi-1B downregulation, which is maximal at 1-2 h of EPO stimulation.
Combining our findings (along with those of others) reveals a scheme whereby STAT5 can control cytokine-response genes through two mechanisms. Although our studies are confined to EPO signaling, we speculate that such a scheme is more general, given the multitude of cytokines that activate STAT5. Furthermore, others have demonstrated that stimulation of myelomonocytic M1 cells with interleukin-6, which activates STAT3, results in Gfi-1B down-regulation (22) . As shown in Fig. 8 , in the absence of cytokine signaling (indicated by dashed lines), GFI-1B is abundant and represses the promoters of STAT5 targets such as Socs1, Socs3, and p21
Waf1 (22, 38) . Upon cytokine stimulation (solid lines), activation of STAT5, in addition to causing direct activation of its target genes, allows Gfi-1B levels to decline, thereby relieving direct repression of these promoters. It would be interesting to determine whether other transcriptional repressors regulate those STAT target genes that are not regulated by GFI-1B. STAT5 phosphorylation is maximal within minutes of cytokine stimulation, whereas Gfi-1B down-regulation is maximal after 1-2 h of cytokine stimulation. Thus, initial induction of Socs genes is attributable to transcriptional activation of their promoters by STAT5, whereas maintenance of Socs1 and Socs3 levels can be achieved, in part, through relief of transcriptional repression by GFI-1B. These results underscored the importance of multi-level control of Socs gene expression in tightly regulated cytokine-mediated effects. , Socs1, and Socs3. Upon EPO addition, STAT5 is activated, resulting in, through new protein synthesis (??), reduced Gfi-1B levels and therefore release of its inhibitory effects on STAT target genes. Thus, STAT5 up-regulates the transcript levels of target genes through at least two mechanisms, one through direct binding and activation and one through down-regulation of transcriptional repressors such as GFI-1B.
